Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

INTRODUCTION: The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A). METHODS: Pre-treatment BMD of 213 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Markopoulos, Christos, Tzoracoleftherakis, Evagelos, Polychronis, Athanassios, Venizelos, Basileios, Dafni, Urania, Xepapadakis, Grigorios, Papadiamantis, John, Zobolas, Vasilios, Misitzis, John, Kalogerakos, Kyriakos, Sarantopoulou, Angeliki, Siasos, Nikolaos, Koukouras, Dimitrios, Antonopoulou, Zoh, Lazarou, Spyros, Gogas, Helen
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879572/
https://www.ncbi.nlm.nih.gov/pubmed/20398352
http://dx.doi.org/10.1186/bcr2565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879572/
https://www.ncbi.nlm.nih.gov/pubmed/20398352
http://dx.doi.org/10.1186/bcr2565

Ejemplares similares